Clinical trials
Breast Cancer Female clinical trials
Below are recruiting breast cancer female clinical trials, each written for real people, not researchers. We’re tracking 1,100 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05891093RecruitingPhase 3
Fluzoparib plus hormone therapy after surgery for breast cancer
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
Beijing, Beijing MunicipalityAges 18–70 - NCT05635487RecruitingPhase 2
Neoadjuvant treatment for HER2-positive breast cancer with SHR-A1811
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
Shenyang, LiaoningAges 18–75 - NCT06387628RecruitingPhase 2
LM-108 with immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06548919Recruiting
Treatment patterns for ESR1-mutated advanced breast cancer
This study looks at how Chinese patients with a specific gene change (ESR1 mutation) in ER-positive, HER2-negative advanced breast cancer are currently being treated. It will help doctors understand what treatments work best for people whose cancer has stopped responding to hormone therapy.
Suzhou, JiangsuAges 18 years+ - NCT07753226RecruitingPhase 1
Study of SI-B036 for advanced breast cancer and other solid tumors
This study tests a new drug called SI-B036 for people with advanced breast cancer or other solid tumors that have spread. The goal is to see if the drug is safe and to find the best dose.
Beijing, Beijing MunicipalityAges 18–75 - NCT07612215RecruitingPhase 1/Phase 2
Elacestrant for Advanced Triple-Positive Breast Cancer
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
New York, New YorkAges 18 years+ - NCT07600957Recruiting
Polarized Light Therapy to Ease Radiation Skin Damage
This trial tests whether a special type of light therapy can reduce skin damage and irritation that happens during radiation treatment for breast cancer. If it works, it could help patients feel more comfortable during and after their radiation therapy.
Banī SuwayfAges 35–55 - NCT06171360Recruiting
Gut bacteria and CDK4/6 inhibitor treatment in breast cancer
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
BrusselsAges 18–100 - NCT07461454RecruitingPhase 3
Comparing YL202 to other treatments for HR+/HER2- breast cancer
This trial tests a new drug called YL202 against other treatments chosen by your doctor for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to see if YL202 works better. You may join if your cancer has spread, you've already tried chemotherapy, and you meet other health criteria.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04872166RecruitingPhase 1
BTX-A51 for advanced solid tumors and breast cancer patients
This Phase 1 study tests BTX-A51, an experimental treatment, in people with advanced cancers that can’t be cured with standard options. It mainly focuses on safety, side effects, and whether the drug can start helping certain tumors.
Lake Mary, FloridaAges 18 years+ - NCT07441460RecruitingPhase 3
KN026 plus HB1801 after surgery for HER2-positive breast cancer
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07389733RecruitingPhase 1/Phase 2
Study of HRS-6208 with other drugs for advanced breast cancer
This trial tests a new combination of drugs (HRS-6208 with HRS-8080, fulvestrant, or letrozole) for people with advanced or metastatic breast cancer that cannot be removed by surgery. It aims to see if these combinations can help shrink or slow the cancer.
Dalian, LiaoningAges 18–75 - NCT07396324RecruitingPhase 2
A new drug before surgery for HR+ HER2- breast cancer
This trial tests whether the drug QL1706, given before surgery, can help treat hormone receptor positive and HER2-negative breast cancer. It is for people who have not yet had cancer spread to other parts of the body.
ShanghaiAges 18 years+ - NCT06851299RecruitingPhase 2
Trop2-ADC alone or with immunotherapy for advanced triple-negative breast cancer
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–70 - NCT07235176RecruitingPhase 1/Phase 2
QLS1304 plus hormone therapy for ER+ breast cancer
This trial tests a new drug called QLS1304 combined with hormone therapy for people with ER-positive, HER2-negative breast cancer that has spread or come back and no longer responds to hormone therapy alone. The goal is to see if this combination can help shrink tumors or slow the disease.
ShanghaiAges 18 years+ - NCT07237256RecruitingPhase 3
Testing less chemo for HR+ HER2- breast cancer with ribociclib
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
AmiensAges 18 years+ - NCT07166185Recruiting
Targeted therapy before surgery for HER2+ breast cancer
This trial tests a combination of two targeted drugs (trastuzumab and pertuzumab) given as a shot under the skin before surgery for women with a specific type of breast cancer called HER2-positive. The goal is to see if this treatment works well for women in Algeria.
BlidaAges 19 years+ - NCT07136428RecruitingPhase 1/Phase 2
Asciminib for HER2+ breast cancer that has spread to the brain
This trial tests the drug asciminib for people with HER2-positive breast cancer that has spread to the brain and is growing. It may be an option if you have already tried standard treatments like T-DXd and tucatinib.
Durham, North CarolinaAges 18 years+ - NCT07087691Recruiting
Testing a device to mark breast cancer for surgery and monitoring
This trial tests a device called OneMark that helps doctors find and track breast cancer during surgery and follow-up. It may help make sure the cancer is removed completely.
La Jolla, CaliforniaAges 18 years+ - NCT07047365RecruitingPhase 3
New drug for HER2-positive advanced breast cancer
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
Bengbu, AnhuiAges 18–75 - NCT07032545Recruiting
Broccoli microgreens study for obese breast cancer survivors
This trial tests if eating broccoli microgreens can improve metabolism in obese breast cancer survivors. Participants will avoid other cruciferous vegetables during the study to see how the microgreens affect their health.
Baltimore, MarylandAges Any age - NCT06892093Recruiting
Probiotics to prevent diarrhea from neratinib in breast cancer
This trial tests whether taking probiotics can help prevent diarrhea caused by the breast cancer drug neratinib. If you are a woman with HER2-positive breast cancer and are about to start neratinib, this study may help manage a common side effect.
Guangzhou, GuangdongAges 18 years+ - NCT05744687RecruitingPhase 2/Phase 3
Letrozole plus SPH4336 versus letrozole alone for breast cancer
This study tests whether adding SPH4336 to letrozole works better than letrozole plus a placebo for treating hormone-receptor–positive, HER2-negative breast cancer in people starting first-line treatment. It may help slow cancer growth more effectively if the added drug is beneficial.
Fuzhou, FujianAges 18–75 - NCT06609187RecruitingPhase 1
Study of GNC-077 for advanced breast cancer and other solid tumors
This trial tests a new drug called GNC-077 for people with advanced breast cancer or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer female?
- Yes. Clin2 currently lists 1,100 recruiting breast cancer female studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer female trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer female trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.